Programme Day 3

09.00 - 10.00

Venous Thrombosis: Consequences
Oral Communications
Hall: Lomond

Modeartors: Willem Lijfering (The Netherlands) and Giordano Pula (United Kingdom)

  • 09.00 – 09.15: Increased mortality risk after venous thrombosis: MEGA follow-up study, Nienke Wit, The Netherlands
  • 09.15 – 09.30: Thromboembolic and Bleeding Complications in Patients with Atrial Fibrillation and Liver Cirrhosis – a Population-based Cohort Study, Emil Zâl Riahi, Denmark
  • 09.30 – 09.45: Rosuvastatin use decreases FVIII levels by mechanisms not associated with the cholesterol-lowering effect of the drug: results from the START trial, Willem Lijfering, The Netherlands
  • 09.45 – 10.00: Survival after cancer-related venous thrombosis: the Scandinavian Thrombosis and Cancer Study (STAC), Rayna Anijs, The Netherlands

Bleeding in the Clinic
Oral Communications
Hall: Alsh


Moderators: Matthew Sims (United Kingdom) and Nadine Ajzenberg (France)

  • 09.00 – 09.15: The VWF variant D1472H affects VWF binding to ristocetin in vitro : the usefulness of measuring VWF activity with the Innovance® VWF:GpIbM assay to avoid VWD genotyping, Fanny Lassalle, France
  • 09.15 – 09.30: Neither a structured questionnaire at pre-anesthesia visit nor the prescription of routine hemostatic tests have acceptable performances to detect hemostatic abnormalities before surgery, Nadine Ajzenberg, France
  • 09.30 – 09.45: The effect of direct oral anticoagulants on bleeding and blood product usage in adults undergoing major cardiac surgery compared with warfarin and control groups, Christopher Little, United Kingdom
  • 09.45 – 10.00: Evaluation of Provision of external quality assurance for thromboelastography cartridge based systems: TEG6 and Rotem Sigma, Dianne Kitchen, United Kingdom

Clot Structure
Oral Communications
Hall: Boisdale



Moderators: Michael Callaghan (United States) and Lucas Di Meglio (France)

  • 09.00 – 09.15: Cells of the macrophage lineage secrete factor (F)XIII-A into the plasma, Richard Pease, United Kingdom
  • 9.15 – 9.30: Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis, Lucas Di Meglio, France
  • 09.30 – 09.45: Role of the fibrin αC region in mechanical strength, resistance to fibrinolysis and formation of a stable whole blood clot, Helen Mcpherson, United Kingdom
  • 09.45 – 10.00: A newly established murine model shows that fibrin γ-chain cross-linking protects against clot embolization, Cédric Duval, United Kingdom

Vessel Wall 2
Oral Communications
Hall: Carron



Moderators: Parvathy Sasikumar (United Kingdom) and Sophie Dolleman (The Netherlands)

  • 09.00 – 09.15: An endothelial-enriched G protein-coupled receptor regulates tissue factor expression, Marthe Norreen Thorsen, Norway
  • 09.15 – 09.30: Evaluation of a novel mouse model of abdominal aortic aneurysm to study platelet mechanisms of the proinflammatory thrombus, Katia Yahiaoui, France
  • 09.30 – 09.45: Thrombin in complex with dabigatran can still activate PAR-1 on endothelial cells, Sophie Dolleman, The Netherlands
  • 09.45 – 10.00: The endothelial-enriched protein KANK3 regulates cell motility and tissue factor expression, Eike Struck, Norway

10.00 - 10.30

Coffee Break & Poster Viewing

10.30 - 11.00

State of the Art

Overview on HUS: novel treatment

Miriam Galbusera


Hall: Lomond

Moderators: Gaia Zirka (France) and Jim Crawley (United Kingdom)

State of the Art

Phosphatases in platelet signalling

Yotis Senis

United Kingdom

Hall: Alsh

Moderators: Judith Cosemans, the Netherlands and Tom van de Berg (The Netherlands)

11.00 - 11.30

State of the Art


Kimberly Martinod


Hall: Lomond

Moderators: Gaia Zirka (France) and Jim Crawley (United Kingdom)

State of the Art


Samantha Gouw

The Netherlands

Hall: Alsh

Moderators: Judith Cosemans, the Netherlands and Tom van de Berg (The Netherlands)

11.30 - 12.30

Science, Fast and Furious
Hall: Lomond

Moderators: Tom van de Berg (The Netherlands) and Banne Nemeth (The Netherlands)

  • 11.30 – 11.45: Platelet-derived chemokines CCL5 and CXCL4 are rapidly internalized in endothelial cells, Annemiek Dickhout, The Netherlands
  • 11.45 – 12.00: Combined effects of five prothrombotic genotypes and cancer on the risk of venous thromboembolism, Hanne Skille, Norway
  • 12.00 – 12.15: ADAMTS13 conformation in the French cohort of child-onset acquired thrombotic thrombocytopenic purpura, Bérangère Joly, France
  • 12.15 – 12.30: The importance of the GPIbα intracellular tail in VWF- and GPVI-mediated platelet signalling events, Isabelle Salles-Crawley, United Kingdom

12.30 - 13.30

Lunch Break & Poster Viewing

Sport Activity

13.30 - 14.30

Plenary Lecture

Current status of inhibitors of factor XI

Jeffrey Weitz


Hall: Lomond

Moderator: Pierre Morange (France)

14.30 - 14.45

Closing and ECTH2021